# ProfoundBio

Source: https://onco.cc/companies/profoundbio/  
OnCo record `profoundbio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ProfoundBio developed antibodies that deliver a chemotherapy drug to ovarian cancer cells carrying a protein called folate receptor alpha. Genmab bought the company for 1.8 billion dollars in 2024.

## Summary

ProfoundBio was a privately owned, clinical-stage Seattle biotech developing next-generation antibody-drug conjugates and ADC linker-payload technology. Its lead asset rinatabart sesutecan (Rina-S) is a folate receptor alpha (FRα)-targeted topoisomerase 1 inhibitor ADC designed to treat a broader FRα-expressing population than first-generation FRα ADCs; at acquisition it was in the phase 2 portion of a phase 1/2 trial in ovarian cancer and other FRα-expressing solid tumours, and had received FDA Fast Track designation in January 2024 for FRα-expressing platinum-resistant ovarian cancer. Genmab agreed in April 2024 to acquire ProfoundBio for USD 1.8 billion in cash, gaining three clinical-stage candidates and the ADC platforms; the deal closed in May 2024 and the ProfoundBio domain now redirects to genmab.com.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Seattle, WA
- Type: biotech
- Website: https://www.genmab.com/

## Notes

- profoundbio.com redirects to genmab.com, recorded as the website. Pre-acquisition venture rounds (reported elsewhere as a 2023 Series B) not sourced and omitted. ir.genmab.com returned HTTP 403 to my fetches.

## Sources

- Official website: https://www.genmab.com/
- Genmab acquisition announcement (Nasdaq copy): https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/)
- companies: [Genmab](https://onco.cc/companies/genmab/), [Medicxi](https://onco.cc/companies/medicxi/)

---
JSON: https://onco.cc/api/v1/entities/profoundbio.json